CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress Provides interested parties with the ability to ask questions and submit topics for ...

The Company continues to expand its current ADC pipeline to encompass multiple targets, such as AKTX-101 (Trop2 ADC with PH1 payload), as well as future programs (AKTX-102, undisclosed target with PH1 ...

Uncover how mixed-signal ICs are transforming medical wearables with smaller and more power-efficient sensor integration, ...

Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced its abstract has been accepted for oral presentation ...

Cellenkos® Inc., a clinical-stage biotechnology company focused on developing allogeneic, off-the-shelf, T regulatory (Treg) cell therapies for autoimmune diseases and inflammatory disorders ...

Given the critical importance of endocytosis detection in ADC research and development, ACROBiosystems has designed an ...

Generating a deterministic dither waveform to DC signals in order to enhance the signal-to-quantization noise of ADC ...

ADC usage in breast cancer treatment increased 3.7-fold from 2021 to 2023, with significant reductions in median time to ...

From this core mechanism Fc engineering has evolved over time into the "engine" of therapeutic antibody development. It ...

Patients with an aggressive form of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed ...

Jonathan: assure me that I’ll be the candidate Mark: Presidential ticket is open to all Obi also wants assurance he’ll be picked Atiku set to formally join party, declare ambition The closed door ...

Does Generation Z have the values employers are looking for, or has the culture shifted to individual happiness that has less to do with monetary success and career achievement? NYU Stern School of ...